Data from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01) Article Swipe
Anne F. de Groot
,
Danielle Cohen
,
Joan B. Heijns
,
Caroline M.P.W. Mandigers
,
Agnès J. van de Wouw
,
Marissa Cloos‐van Balen
,
Joanna A. Ropela
,
Hendrika M. Oosterkamp
,
Marlies L. van Bekkum
,
Danny Houtsma
,
Hein Putter
,
Elma Meershoek‐Klein Kranenbarg
,
Marjolijn Duijm‐de Carpentier
,
Kyra L. Dijkstra
,
A. Elise van Leeuwen‐Stok
,
Sjoerd H. van der Burg
,
Gerrit‐Jan Liefers
,
Sabine C. Linn
,
Judith R. Kroep
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.c.7960492
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.c.7960492
Purpose:In hormone receptor–positive, HER2-negative, early-stage breast cancer, cyclin-dependent kinase 4 and 6 inhibition combined with endocrine therapy could represent a less toxic alternative to neoadjuvant chemotherapy (CT). The NEOLBC trial studied whether neoadjuvant ribociclib plus letrozole (RL) results in a doubling of complete cell-cycle arrest (CCCA; Ki67 <1% on IHC) compared with CT in the surgical specimen in luminal breast cancer.Patients and Methods:This randomized phase II trial tailored neoadjuvant therapy in postmenopausal patients with early, luminal, HER2-negative, stage II/III breast cancer based on the percentage of Ki67-positive cancer cells after 2 weeks of letrozole. Patients with a Ki67 ≥1% were randomized between RL and standard CT. Secondary endpoints included pathologic response and toxicity.Results:Of 161 registered patients, 70 were randomized, and 66 started the allocated treatment. The CCCA in the surgical specimen was similar for both groups: 35.3% in the RL group and 31.3% in the CT group (P = 0.73). The response according to Miller and Payne was not significantly different between the two groups, nor was the pathologic complete response rate. Overall toxicity was observed more often in the CT group. In the RL group, eight patients discontinued treatment due to toxicity, and in the CT group, 10 patients discontinued treatment.Conclusions:Although the primary endpoint was not met, the NEOLBC trial (NCT03283384) showed a similar CCCA and pathologic response for RL and CT with less toxicity. Therefore, RL as an alternative to neoadjuvant CT merits further investigation.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1158/1078-0432.c.7960492
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4412818551
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4412818551Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1078-0432.c.7960492Digital Object Identifier
- Title
-
Data from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)Work title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-08-01Full publication date if available
- Authors
-
Anne F. de Groot, Danielle Cohen, Joan B. Heijns, Caroline M.P.W. Mandigers, Agnès J. van de Wouw, Marissa Cloos‐van Balen, Joanna A. Ropela, Hendrika M. Oosterkamp, Marlies L. van Bekkum, Danny Houtsma, Hein Putter, Elma Meershoek‐Klein Kranenbarg, Marjolijn Duijm‐de Carpentier, Kyra L. Dijkstra, A. Elise van Leeuwen‐Stok, Sjoerd H. van der Burg, Gerrit‐Jan Liefers, Sabine C. Linn, Judith R. KroepList of authors in order
- Landing page
-
https://doi.org/10.1158/1078-0432.c.7960492Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/1078-0432.c.7960492Direct OA link when available
- Concepts
-
Letrozole, Medicine, Oncology, Breast cancer, Internal medicine, Chemotherapy, Cancer, TamoxifenTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4412818551 |
|---|---|
| doi | https://doi.org/10.1158/1078-0432.c.7960492 |
| ids.doi | https://doi.org/10.1158/1078-0432.c.7960492 |
| ids.openalex | https://openalex.org/W4412818551 |
| fwci | 0.0 |
| type | article |
| title | Data from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01) |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T12829 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9983999729156494 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Advanced Breast Cancer Therapies |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2778812593 |
| concepts[0].level | 5 |
| concepts[0].score | 0.8705271482467651 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q194974 |
| concepts[0].display_name | Letrozole |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.7422728538513184 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C143998085 |
| concepts[2].level | 1 |
| concepts[2].score | 0.7258583307266235 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[2].display_name | Oncology |
| concepts[3].id | https://openalex.org/C530470458 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5898841023445129 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q128581 |
| concepts[3].display_name | Breast cancer |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5733109712600708 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C2776694085 |
| concepts[5].level | 2 |
| concepts[5].score | 0.56724613904953 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[5].display_name | Chemotherapy |
| concepts[6].id | https://openalex.org/C121608353 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5149939656257629 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[6].display_name | Cancer |
| concepts[7].id | https://openalex.org/C2777176818 |
| concepts[7].level | 4 |
| concepts[7].score | 0.18365240097045898 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q412178 |
| concepts[7].display_name | Tamoxifen |
| keywords[0].id | https://openalex.org/keywords/letrozole |
| keywords[0].score | 0.8705271482467651 |
| keywords[0].display_name | Letrozole |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.7422728538513184 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/oncology |
| keywords[2].score | 0.7258583307266235 |
| keywords[2].display_name | Oncology |
| keywords[3].id | https://openalex.org/keywords/breast-cancer |
| keywords[3].score | 0.5898841023445129 |
| keywords[3].display_name | Breast cancer |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.5733109712600708 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/chemotherapy |
| keywords[5].score | 0.56724613904953 |
| keywords[5].display_name | Chemotherapy |
| keywords[6].id | https://openalex.org/keywords/cancer |
| keywords[6].score | 0.5149939656257629 |
| keywords[6].display_name | Cancer |
| keywords[7].id | https://openalex.org/keywords/tamoxifen |
| keywords[7].score | 0.18365240097045898 |
| keywords[7].display_name | Tamoxifen |
| language | en |
| locations[0].id | doi:10.1158/1078-0432.c.7960492 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1078-0432.c.7960492 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5021568700 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-7612-2918 |
| authorships[0].author.display_name | Anne F. de Groot |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Anne F. de Groot |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5078547921 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-6004-9402 |
| authorships[1].author.display_name | Danielle Cohen |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Danielle Cohen |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5059039439 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Joan B. Heijns |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Joan B. Heijns |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5113774347 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-7791-2049 |
| authorships[3].author.display_name | Caroline M.P.W. Mandigers |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Caroline M.P.W. Mandigers |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5065928405 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-2229-3970 |
| authorships[4].author.display_name | Agnès J. van de Wouw |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Agnes J. van de Wouw |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5025920150 |
| authorships[5].author.orcid | https://orcid.org/0009-0002-3050-9839 |
| authorships[5].author.display_name | Marissa Cloos‐van Balen |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Marissa Cloos-van Balen |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5000595320 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Joanna A. Ropela |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Joanna A. Ropela |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5063173912 |
| authorships[7].author.orcid | https://orcid.org/0009-0003-0778-5808 |
| authorships[7].author.display_name | Hendrika M. Oosterkamp |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Hendrika M. Oosterkamp |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5075041827 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Marlies L. van Bekkum |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Marlies L. van Bekkum |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5024659972 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-8792-0368 |
| authorships[9].author.display_name | Danny Houtsma |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Danny Houtsma |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5073613763 |
| authorships[10].author.orcid | https://orcid.org/0000-0001-5395-1422 |
| authorships[10].author.display_name | Hein Putter |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Hein Putter |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5048152930 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-1750-2221 |
| authorships[11].author.display_name | Elma Meershoek‐Klein Kranenbarg |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Elma Meershoek-Klein Kranenbarg |
| authorships[11].is_corresponding | False |
| authorships[12].author.id | https://openalex.org/A5006221087 |
| authorships[12].author.orcid | https://orcid.org/0000-0001-7109-1542 |
| authorships[12].author.display_name | Marjolijn Duijm‐de Carpentier |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Marjolijn Duijm-de Carpentier |
| authorships[12].is_corresponding | False |
| authorships[13].author.id | https://openalex.org/A5048040497 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-6181-3983 |
| authorships[13].author.display_name | Kyra L. Dijkstra |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Kyra L. Dijkstra |
| authorships[13].is_corresponding | False |
| authorships[14].author.id | https://openalex.org/A5059199132 |
| authorships[14].author.orcid | https://orcid.org/0000-0003-1988-4099 |
| authorships[14].author.display_name | A. Elise van Leeuwen‐Stok |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | A. Elise van Leeuwen-Stok |
| authorships[14].is_corresponding | False |
| authorships[15].author.id | https://openalex.org/A5041281028 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-6556-0354 |
| authorships[15].author.display_name | Sjoerd H. van der Burg |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Sjoerd H. van der Burg |
| authorships[15].is_corresponding | False |
| authorships[16].author.id | https://openalex.org/A5031880856 |
| authorships[16].author.orcid | https://orcid.org/0000-0001-7326-8313 |
| authorships[16].author.display_name | Gerrit‐Jan Liefers |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Gerrit-Jan Liefers |
| authorships[16].is_corresponding | False |
| authorships[17].author.id | https://openalex.org/A5063917865 |
| authorships[17].author.orcid | https://orcid.org/0000-0001-5541-0347 |
| authorships[17].author.display_name | Sabine C. Linn |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Sabine C. Linn |
| authorships[17].is_corresponding | False |
| authorships[18].author.id | https://openalex.org/A5021122880 |
| authorships[18].author.orcid | https://orcid.org/0000-0003-2671-1903 |
| authorships[18].author.display_name | Judith R. Kroep |
| authorships[18].author_position | last |
| authorships[18].raw_author_name | Judith R. Kroep |
| authorships[18].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/1078-0432.c.7960492 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Data from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01) |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T12829 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9983999729156494 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Advanced Breast Cancer Therapies |
| related_works | https://openalex.org/W4391375266, https://openalex.org/W3171632527, https://openalex.org/W2048424035, https://openalex.org/W2374415868, https://openalex.org/W4283756545, https://openalex.org/W2745360070, https://openalex.org/W3214977210, https://openalex.org/W2039173563, https://openalex.org/W3048848035, https://openalex.org/W2892677547 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/1078-0432.c.7960492 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1078-0432.c.7960492 |
| primary_location.id | doi:10.1158/1078-0432.c.7960492 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1078-0432.c.7960492 |
| publication_date | 2025-08-01 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.2 | 90 |
| abstract_inverted_index.4 | 9 |
| abstract_inverted_index.6 | 11 |
| abstract_inverted_index.= | 148 |
| abstract_inverted_index.a | 19, 39, 96, 213 |
| abstract_inverted_index.10 | 198 |
| abstract_inverted_index.66 | 120 |
| abstract_inverted_index.70 | 116 |
| abstract_inverted_index.CT | 52, 145, 180, 196, 222, 233 |
| abstract_inverted_index.II | 65 |
| abstract_inverted_index.In | 182 |
| abstract_inverted_index.RL | 102, 139, 184, 220, 227 |
| abstract_inverted_index.an | 229 |
| abstract_inverted_index.as | 228 |
| abstract_inverted_index.in | 38, 53, 57, 70, 127, 137, 143, 178, 194 |
| abstract_inverted_index.of | 41, 85, 92 |
| abstract_inverted_index.on | 48, 82 |
| abstract_inverted_index.to | 23, 153, 191, 231 |
| abstract_inverted_index.161 | 113 |
| abstract_inverted_index.CT. | 105 |
| abstract_inverted_index.The | 27, 125, 150 |
| abstract_inverted_index.and | 10, 61, 103, 111, 119, 141, 155, 193, 216, 221 |
| abstract_inverted_index.due | 190 |
| abstract_inverted_index.for | 133, 219 |
| abstract_inverted_index.nor | 165 |
| abstract_inverted_index.not | 158, 206 |
| abstract_inverted_index.the | 54, 83, 122, 128, 138, 144, 162, 167, 179, 183, 195, 202, 208 |
| abstract_inverted_index.two | 163 |
| abstract_inverted_index.was | 131, 157, 166, 174, 205 |
| abstract_inverted_index.(RL) | 36 |
| abstract_inverted_index.CCCA | 126, 215 |
| abstract_inverted_index.IHC) | 49 |
| abstract_inverted_index.Ki67 | 46, 97 |
| abstract_inverted_index.both | 134 |
| abstract_inverted_index.less | 20, 224 |
| abstract_inverted_index.met, | 207 |
| abstract_inverted_index.more | 176 |
| abstract_inverted_index.plus | 34 |
| abstract_inverted_index.were | 99, 117 |
| abstract_inverted_index.with | 14, 51, 73, 95, 223 |
| abstract_inverted_index.(CT). | 26 |
| abstract_inverted_index.31.3% | 142 |
| abstract_inverted_index.35.3% | 136 |
| abstract_inverted_index.Payne | 156 |
| abstract_inverted_index.after | 89 |
| abstract_inverted_index.based | 81 |
| abstract_inverted_index.cells | 88 |
| abstract_inverted_index.could | 17 |
| abstract_inverted_index.eight | 186 |
| abstract_inverted_index.group | 140, 146 |
| abstract_inverted_index.often | 177 |
| abstract_inverted_index.phase | 64 |
| abstract_inverted_index.rate. | 171 |
| abstract_inverted_index.stage | 77 |
| abstract_inverted_index.toxic | 21 |
| abstract_inverted_index.trial | 29, 66, 210 |
| abstract_inverted_index.weeks | 91 |
| abstract_inverted_index.≥1% | 98 |
| abstract_inverted_index.<1% | 47 |
| abstract_inverted_index.(CCCA; | 45 |
| abstract_inverted_index.0.73). | 149 |
| abstract_inverted_index.II/III | 78 |
| abstract_inverted_index.Miller | 154 |
| abstract_inverted_index.NEOLBC | 28, 209 |
| abstract_inverted_index.arrest | 44 |
| abstract_inverted_index.breast | 5, 59, 79 |
| abstract_inverted_index.cancer | 80, 87 |
| abstract_inverted_index.early, | 74 |
| abstract_inverted_index.group, | 185, 197 |
| abstract_inverted_index.group. | 181 |
| abstract_inverted_index.kinase | 8 |
| abstract_inverted_index.merits | 234 |
| abstract_inverted_index.showed | 212 |
| abstract_inverted_index.Overall | 172 |
| abstract_inverted_index.between | 101, 161 |
| abstract_inverted_index.cancer, | 6 |
| abstract_inverted_index.further | 235 |
| abstract_inverted_index.groups, | 164 |
| abstract_inverted_index.groups: | 135 |
| abstract_inverted_index.hormone | 1 |
| abstract_inverted_index.luminal | 58 |
| abstract_inverted_index.primary | 203 |
| abstract_inverted_index.results | 37 |
| abstract_inverted_index.similar | 132, 214 |
| abstract_inverted_index.started | 121 |
| abstract_inverted_index.studied | 30 |
| abstract_inverted_index.therapy | 16, 69 |
| abstract_inverted_index.whether | 31 |
| abstract_inverted_index.Patients | 94 |
| abstract_inverted_index.combined | 13 |
| abstract_inverted_index.compared | 50 |
| abstract_inverted_index.complete | 42, 169 |
| abstract_inverted_index.doubling | 40 |
| abstract_inverted_index.endpoint | 204 |
| abstract_inverted_index.included | 108 |
| abstract_inverted_index.luminal, | 75 |
| abstract_inverted_index.observed | 175 |
| abstract_inverted_index.patients | 72, 187, 199 |
| abstract_inverted_index.response | 110, 151, 170, 218 |
| abstract_inverted_index.specimen | 56, 130 |
| abstract_inverted_index.standard | 104 |
| abstract_inverted_index.surgical | 55, 129 |
| abstract_inverted_index.tailored | 67 |
| abstract_inverted_index.toxicity | 173 |
| abstract_inverted_index.Secondary | 106 |
| abstract_inverted_index.according | 152 |
| abstract_inverted_index.allocated | 123 |
| abstract_inverted_index.different | 160 |
| abstract_inverted_index.endocrine | 15 |
| abstract_inverted_index.endpoints | 107 |
| abstract_inverted_index.letrozole | 35 |
| abstract_inverted_index.patients, | 115 |
| abstract_inverted_index.represent | 18 |
| abstract_inverted_index.toxicity, | 192 |
| abstract_inverted_index.toxicity. | 225 |
| abstract_inverted_index.treatment | 189 |
| abstract_inverted_index.Therefore, | 226 |
| abstract_inverted_index.cell-cycle | 43 |
| abstract_inverted_index.inhibition | 12 |
| abstract_inverted_index.letrozole. | 93 |
| abstract_inverted_index.pathologic | 109, 168, 217 |
| abstract_inverted_index.percentage | 84 |
| abstract_inverted_index.randomized | 63, 100 |
| abstract_inverted_index.registered | 114 |
| abstract_inverted_index.ribociclib | 33 |
| abstract_inverted_index.treatment. | 124 |
| abstract_inverted_index.alternative | 22, 230 |
| abstract_inverted_index.early-stage | 4 |
| abstract_inverted_index.neoadjuvant | 24, 32, 68, 232 |
| abstract_inverted_index.randomized, | 118 |
| abstract_inverted_index.chemotherapy | 25 |
| abstract_inverted_index.discontinued | 188, 200 |
| abstract_inverted_index.(NCT03283384) | 211 |
| abstract_inverted_index.Ki67-positive | 86 |
| abstract_inverted_index.significantly | 159 |
| abstract_inverted_index.HER2-negative, | 3, 76 |
| abstract_inverted_index.postmenopausal | 71 |
| abstract_inverted_index.cyclin-dependent | 7 |
| abstract_inverted_index.receptor–positive, | 2 |
| abstract_inverted_index.(<i>P</i> | 147 |
| abstract_inverted_index.Methods:<p>This | 62 |
| abstract_inverted_index.cancer.</p>Patients | 60 |
| abstract_inverted_index.investigation.</p></div> | 236 |
| abstract_inverted_index.<div>AbstractPurpose:<p>In | 0 |
| abstract_inverted_index.toxicity.</p>Results:<p>Of | 112 |
| abstract_inverted_index.treatment.</p>Conclusions:<p>Although | 201 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 19 |
| citation_normalized_percentile.value | 0.46180987 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |